Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Post-Transplant Events

Reduced efficacy of topical corticosteroid in preventing cytarabine-induced kerato-conjunctivitis in patients receiving high-dose cytarabine and total body irradiation for allogeneic hematopoietic stem cell transplantation

Bone Marrow Transplantation volume 42, pages 197–199 (2008)Cite this article

Abstract

This study aimed to retrospectively evaluate the incidence of kerato-conjunctivitis in patients receiving TBI followed by high-dose cytarabine, and to clarify how effectively topical corticosteroid eye drops prevent kerato-conjunctivitis in these patients. Fifty-three patients who received cytarabine at a dose of 3 g/m2 every 12 h for 4 days after receiving TBI (12 Gy) as a conditioning for allogeneic hematopoietic stem cell transplantation (HSCT) were evaluated. For the prophylaxis of kerato-conjunctivitis, all patients received betamethasone sodium phosphate eye drops every 6 h, starting 1 day before the first dose of cytarabine and continuing until 1 day after the last dose of cytarabine or the complete resolution of ocular symptoms. For grading of kerato-conjuncitivitis, the National Cancer Institute-Common Toxicity Criteria were used. Among the 53 patients, the grades of kerato-conjunctivitis were grade 0 in 13 patients, grade 1 in 6 patients (11.3%), grade 2 in 10 patients (18.9%) and grade 3 in 25 patients (47.2%). These results strongly suggest that topical corticosteroid eye drops could not effectively prevent the development of cytarabine-induced kerato-conjunctivitis in HSCT recipients who receive high-dose cytarabine following TBI. Further investigation into a more effective prophylaxis for cytarabine-induced kerato-conjunctivitis in this setting is required.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Similar content being viewed by others

References

  1. Herzig RH, Wolff SN, Lazarus HM, Phillips GL, Karanes C, Herzig GP . High-dose cytosine arabinoside therapy for refractory leukemia. Blood 1983; 62: 361–369.

    CAS  PubMed  Google Scholar 

  2. Al-Tweigeri T, Nabholtz JM, Mackey JR . Ocular toxicity and cancer chemotherapy. Cancer 1996; 78: 1359–1373.

    Article  CAS  PubMed  Google Scholar 

  3. Lass JH, Lazarus HM, Reed MD, Herzig RH . Topical corticosteroid therapy for corneal toxicity from systemically administered cytarabine. Am J Ophthalmol 1982; 94: 617–621.

    Article  CAS  PubMed  Google Scholar 

  4. Coccia PF, Strandjord SE, Warkentin PI, Cheung NK, Gordon EM, Novak LJ et al. High-dose cytosine arabinoside and fractionated total-body irradiation: an improved preparative regimen for bone marrow transplantation of children with acute lymphoblastic leukemia in remission. Blood 1988; 71: 888–893.

    CAS  PubMed  Google Scholar 

  5. Riddell S, Appelbaum FR, Buckner CD, Stewart P, Clift R, Sanders J et al. High-dose cytarabine and total body irradiation with or without cyclophosphamide as a preparative regimen for marrow transplantation for acute leukemia. J Clin Oncol 1988; 6: 576–582.

    Article  CAS  PubMed  Google Scholar 

  6. Kamani N, Bayever E, August CS, Bunin N, Goldwein JW, D'Angio GJ . Fractionated total-body irradiation preceding high-dose cytosine arabinoside as a preparative regimen for bone marrow transplantation in children with acute leukemia. Med Pediatr Oncol 1995; 25: 179–184.

    Article  CAS  PubMed  Google Scholar 

  7. Takahashi S, Okamoto S-I, Shirafuji N, Ikebuchi K, Tani K, Shimane M et al. Recombinant human glycosylated granulocyte colony-stimulating factor (rhG-CSF)-combined regimen for allogeneic bone marrow transplantation in refractory acute myeloid leukemia. Bone Marrow Transplant 1994; 13: 239–245.

    CAS  PubMed  Google Scholar 

  8. Okamoto S, Takahashi S, Wakui M, Ishida A, Tanosaki R, Ikeda Y et al. Treatment of advanced myelodysplastic syndrome with a regimen including recombinant human granulocyte colony-stimulating factor preceding allogeneic bone marrow transplantation. Br J Haematol 1999; 104: 569–573.

    Article  CAS  PubMed  Google Scholar 

  9. Mori T, Aisa Y, Yokoyama A, Nakazato T, Yamazaki R, Shimizu T et al. Total body irradiation and granulocyte colony-stimulating factor-combined high-dose cytarabine as a conditioning regimen in allogeneic hematopoietic stem cell transplantation for advanced myelodysplastic syndrome: a single-institute experience. Bone Marrow Transplant 2007; 39: 217–221.

    Article  CAS  Google Scholar 

  10. Bessell EM, Henk JM, Whitelocke RA, Wright JE . Ocular morbidity after radiotherapy of orbital and conjunctival lymphoma. Eye 1987; 1: 90–96.

    Article  PubMed  Google Scholar 

  11. Letschert JG, González González D, Oskam J, Koornneef L, van Dijk JD, Boukes R et al. Results of radiotherapy in patients with stage I orbital non-Hodgkin's lymphoma. Radiother Oncol 1991; 22: 36–44.

    Article  CAS  PubMed  Google Scholar 

  12. Lazarus HM, Hartnett ME, Reed MD, Murphy BF, Lass JH . Comparison of the prophylactic effects of 2-deoxycytidine and prednisolone for high-dose intravenous cytarabine-induced keratitis. Am J Ophthalmol 1987; 104: 476–480.

    Article  CAS  PubMed  Google Scholar 

  13. Higa GM, Gockerman JP, Hunt AL, Jones MR, Horne BJ . The use of prophylactic eye drops during high-dose cytosine arabinoside therapy. Cancer 1991; 68: 1691–1693.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Hematology, Department of Medicine, Keio University School of Medicine, Tokyo, Japan

    T Mori, Y Aisa, J Kato, Y Ikeda & S Okamoto

  2. Novartis Pharma Program for Clinical Therapeutics of Hematologic Malignancy, Keio University School of Medicine, Tokyo, Japan

    T Mori & J Kato

  3. Department of Nursing, Keio University Hospital, Tokyo, Japan

    M Watanabe, T Kurotori-Sotome, C Ito, K Yamada, T Yashima, N Kobayashi & S Kondo

  4. Department of Ophthalmology, Keio University School of Medicine, Tokyo, Japan

    Y Ogawa & K Tsubota

  5. Department of Radiology,

    N Shigematsu & A Kubo

  6. , Keio University School of Medicine, Tokyo, Japan

    N Shigematsu & A Kubo

Authors
  1. T Mori
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. M Watanabe
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. T Kurotori-Sotome
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. C Ito
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. K Yamada
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. T Yashima
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. N Kobayashi
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. S Kondo
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Y Aisa
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. J Kato
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Y Ogawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. K Tsubota
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. N Shigematsu
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. A Kubo
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. Y Ikeda
    View author publications

    You can also search for this author in PubMed Google Scholar

  16. S Okamoto
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to T Mori.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Mori, T., Watanabe, M., Kurotori-Sotome, T. et al. Reduced efficacy of topical corticosteroid in preventing cytarabine-induced kerato-conjunctivitis in patients receiving high-dose cytarabine and total body irradiation for allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant 42, 197–199 (2008). https://doi.org/10.1038/bmt.2008.152

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/bmt.2008.152

Keywords

This article is cited by

Search

Advanced search

Quick links